Company Description
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies.
Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
| Country | United States |
| Founded | 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Sandeep Kulkarni |
Contact Details
Address: 1489 W. Warm Springs Road, Suite 110 Henderson, Nevada 89014 United States | |
| Phone | 702 825 9872 |
| Website | zurabio.com |
Stock Details
| Ticker Symbol | ZURA |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1855644 |
| CUSIP Number | G9TY5A101 |
| ISIN Number | KYG9TY5A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sandeep Chidambar Kulkarni M.D. | Co-Founder, Chief Executive Officer and Director |
| Kimberly Ann Davis J.D. | Chief Operating Officer, Chief Legal Officer and Corporate Secretary |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer and Head of Development |
| Marlyn Mathew | Vice President of Finance and Accounting and Principal Financial & Accounting Officer |
| Dr. Gary Whale Ph.D. | Chief Technology Officer |
| Theresa Lowry | Chief Human Resources Officer |
| Muzammil Mustufa | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 22, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | SCHEDULE 13G/A | Filing |
| May 7, 2026 | 8-K | Current Report |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | SCHEDULE 13G/A | Filing |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |